$0.00
0.00%
Nasdaq, Thu, Aug 22 2024
ISIN
US04744L1061
Symbol
ATHX
Sector
Industry

Key metrics

Market capitalization $0.00
Enterprise Value $17.56m
P/E (TTM) P/E ratio 0.00
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 219.50
P/S ratio (TTM) P/S ratio 0.00
P/B ratio (TTM) P/B ratio 0.00
Revenue growth (TTM) Revenue growth -98.65%
Revenue (TTM) Revenue $80.00k
EBIT (operating result TTM) EBIT $-41.42m
Free Cash Flow (TTM) Free Cash Flow $-24.71m
Cash position $1.02m
EPS (TTM) EPS $-2.03
Short interest 3.78%
Show more

Is Athersys, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Athersys, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Athersys, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Athersys, Inc.:

Buy
100%

Financial data from Athersys, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
0.08 0.08
99% 99%
100%
- Direct Costs 1.01 1.01
22% 22%
1,263%
-0.93 -0.93
118% 118%
-1,163%
- Selling and Administrative Expenses 9.50 9.50
39% 39%
11,875%
- Research and Development Expense 30 30
59% 59%
37,475%
-40 -40
51% 51%
-50,513%
- Depreciation and Amortization 1.01 1.01
22% 22%
1,263%
EBIT (Operating Income) EBIT -41 -41
51% 51%
-51,771%
Net Profit -38 -38
54% 54%
-46,888%

In millions USD.

Don't miss a Thing! We will send you all news about Athersys, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Athersys, Inc. Stock News

Neutral
Business Wire
10 months ago
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analy...
Positive
InvestorPlace
11 months ago
Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.
Neutral
Business Wire
11 months ago
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the...
More Athersys, Inc. News

Company Profile

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Head office United States
CEO Daniel Camardo
Employees 24
Founded 1995
Website www.athersys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today